TBX3

Summary

TBX3 (T-box transcription factor 3, HGNC:11602) is a protein-coding gene on chromosome 12q24.21, encoding T-box transcription factor TBX3 (O15119). Transcriptional repressor involved in developmental processes. It is haploinsufficient (ClinGen: sufficient evidence).

This gene is a member of a phylogenetically conserved family of genes that share a common DNA-binding domain, the T-box. T-box genes encode transcription factors involved in the regulation of developmental processes. This protein is a transcriptional repressor and is thought to play a role in the anterior/posterior axis of the tetrapod forelimb. Mutations in this gene cause ulnar-mammary syndrome, affecting limb, apocrine gland, tooth, hair, and genital development. Alternative splicing of this gene results in three transcript variants encoding different isoforms; however, the full length nature of one variant has not been determined.

Source: NCBI Gene 6926 — RefSeq curated summary.

At a glance

• Gene–disease (curated): ulnar-mammary syndrome (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 137
• Clinical variants (ClinVar): 670 total — 22 pathogenic, 14 likely-pathogenic
• Phenotypes (HPO): 73
• Cancer driver (intOGen): activating (oncogene-like) across 3 cancer types
• Dosage sensitivity (ClinGen): haploinsufficiency sufficient evidence, triplosensitivity no evidence
• Transcription factor: yes — 29 downstream targets (CollecTRI)
• MANE Select transcript: NM_005996

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11602
Approved symbol	TBX3
Name	T-box transcription factor 3
Location	12q24.21
Locus type	gene with protein product
Status	Approved
Aliases	TBX3-ISO, XHL
Ensembl gene	ENSG00000135111
Ensembl biotype	protein_coding
OMIM	601621
Entrez	6926

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 2 retained_intron

ENST00000257566, ENST00000349155, ENST00000548503, ENST00000552054

RefSeq mRNA: 2 — MANE Select: NM_005996 NM_005996, NM_016569

CCDS: CCDS9175, CCDS9176

Canonical transcript exons

ENST00000349155 — 7 exons

Exon	Start	End
ENSE00000755589	114680879	114681146
ENSE00000918022	114674165	114674835
ENSE00000918024	114677580	114677656
ENSE00001201415	114676313	114676470
ENSE00001201439	114682812	114684175
ENSE00002408640	114679505	114679651
ENSE00002412265	114670255	114672302

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 99.13.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.1712 / max 586.2111, expressed in 1390 samples.

FANTOM5 promoters (15 alternative TSS)

Promoter ID	TPM avg	Samples expressed
133409	12.9297	1366
133416	1.1317	307
133410	0.8289	377
133415	0.4351	160
133408	0.4322	182
206911	0.3950	192
133407	0.3846	168
206910	0.3739	208
206909	0.2850	142
133405	0.2276	95

Top tissues by expression

276 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	99.13	gold quality
right adrenal gland	UBERON:0001233	99.04	gold quality
adrenal cortex	UBERON:0001235	98.91	gold quality
adrenal tissue	UBERON:0018303	98.88	gold quality
left adrenal gland cortex	UBERON:0035825	98.76	gold quality
left adrenal gland	UBERON:0001234	98.73	gold quality
adrenal gland	UBERON:0002369	98.29	gold quality
urethra	UBERON:0000057	97.96	gold quality
stromal cell of endometrium	CL:0002255	97.91	gold quality
seminal vesicle	UBERON:0000998	97.73	gold quality
prostate gland	UBERON:0002367	97.50	gold quality
right lobe of thyroid gland	UBERON:0001119	96.99	gold quality
right lung	UBERON:0002167	96.23	gold quality
left lobe of thyroid gland	UBERON:0001120	95.95	gold quality
thyroid gland	UBERON:0002046	95.85	gold quality
placenta	UBERON:0001987	95.04	gold quality
jejunal mucosa	UBERON:0000399	94.50	gold quality
corpus epididymis	UBERON:0004359	93.98	gold quality
duodenum	UBERON:0002114	93.69	gold quality
tendon of biceps brachii	UBERON:0008188	93.68	gold quality
left ovary	UBERON:0002119	93.32	gold quality
right ovary	UBERON:0002118	93.05	gold quality
penis	UBERON:0000989	93.01	gold quality
endometrium	UBERON:0001295	92.97	gold quality
vagina	UBERON:0000996	92.96	gold quality
endocervix	UBERON:0000458	92.95	gold quality
urinary bladder	UBERON:0001255	92.90	gold quality
decidua	UBERON:0002450	92.79	gold quality
nipple	UBERON:0002030	92.78	gold quality
right lobe of liver	UBERON:0001114	92.18	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-6701	yes	38.40
E-MTAB-5061	yes	11.11
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

29 targets.

Target	Regulation
BGLAP	Repression
BMP4
CDH1	Repression
CDH17
CDKN1A	Repression
CDKN2A	Repression
CSF1
FRZB	Repression
GATA6
GJA1
GJA5	Repression
GJC1
GJC3
HCN4
HNF1B	Repression
IBSP	Repression
JDP2	Unknown
MIR137
NPPA	Repression
ONECUT1	Repression
PTEN
RUNX2	Repression
SHISA3	Repression
SP7	Repression
SPP1
TBX2	Repression
TBX3
TNFRSF11A
TP53	Unknown

JASPAR motifs

Motif	Name	Family
MA1566.1	TBX3	TBX2-related factors
MA1566.2	TBX3	TBX2-related factors
MA1566.3	TBX3	TBX2-related factors

JASPAR matrix evidence (PMIDs): PMID:18829543

Upstream regulators (CollecTRI, top): AP1, CTNNB1, JUNB, MYC, PRDM4, SIRT1, TBX2, TBX3, TCF3, TP53

miRNA regulators (miRDB)

146 targeting TBX3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345

Functional genomics

ClinGen dosage: haploinsufficiency 3 (sufficient evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• Mutations in Tbx3 are responsible for ulnar-mammary syndrome (UMS), an autosomal dominant disorder affecting limb, tooth, hair, apocrine gland and genital development. (PMID:11689487)
• identification of a variant T-site as the essential TBX2/TBX3-binding element in the human p14(ARF) promoter (PMID:12000749)
• Results demonstrate the structural consequences of T-box domain protein 3 point mutations observed in Ulnar-Mammary syndrome and Holt-Oram syndrome patients. (PMID:12005433)
• The results are consistent with the previous finding that UMS is caused by haploinsufficiency of TBX3. (PMID:12116211)
• Overexpression of TBX3 is associated with breast cancer (PMID:15289316)
• increased expression of truncated cSHMT, Tbx3 and utrophin in plasma samples obtained from patients at early stages of ovarian cancer and breast cancer (PMID:16049973)
• A literature review of TBX3 combined with a novel TBX3 mutation in a family with ulnar-mammary syndrome finds an association in mutations that disrupt the TBX3 DNA-binding domain and a higher frequency of severe upper limb malformations and teeth defects. (PMID:16530712)
• Required for heart and limb formation, and is mutated in ulnar-mammary syndrome. (PMID:16556916)
• Data show that Tbx3 plays an important role in osteogenic differentiation and proliferation of human mesenchymal stem cells derived from adipose tissue. (PMID:16955224)
• Nyx2-5 confines recombinant hTBX3 expression to the sinoatrial node & sinus horns in mice. Tbx3 suppresses chamber differentiation–another mechanism by which the Tbx3-positive sinoatrial node is shielded from differentiating into atrial myocardium. (PMID:17234970)
• TBX3 repression to its targets is dependent on HDAC activity. TBX3 may serve as a biomarker for breast cancer. (PMID:18245468)
• Fluorescence in situ hybridization did not show major deletions or duplications at chromosome 22q11 as well as the TBX5/TBX3 region at 12q24.1. (PMID:18726671)
• Tbx2 and Tbx3 may play a dual role during the radial to vertical growth phase transition by both inhibiting senescence via repression of p21(CIP1) expression, and enhancing melanoma invasiveness by decreasing E-cadherin levels. (PMID:18829543)
• TBX3 mRNA expression was significantly higher in metastatic breast cancer than in non-metastatic tumors. (PMID:19218121)
• The mRNA and protein expressions of Tbx3 are markedly upregulated in breast cancer cell lines and tissue samples. (PMID:19403417)
• Studies identified Tbx3 as a key regulator of the SAN phenotype. (PMID:20133910)
• Tbx3 expression was found to be suppressed by AFLL when the expression of tumor suppressor genes p14 and p53 were activated (PMID:20702496)
• pathway that up-regulates TBX3 expression and provides additional evidence that increased levels of TBX3 contribute to metastasis. (PMID:20942798)
• Data show that estrogen signaling expands the pool of functional breast cancer stem-like cells through a paracrine FGF/FGFR/Tbx3 signaling pathway. (PMID:21098263)
• Study indicate mutation of TBX3 gene in the family. (PMID:21199695)
• In situ hybridization reveals Tbx3 and Sox4 to co-localize extensively in the embryo including the atrioventricular and outflow tract cushion mesenchyme and a small area of interventricular myocardium. (PMID:21538160)
• identify a Sp1 element and two CCAAT boxes to be essential for basal TBX3 promoter activity (PMID:21784138)
• Tbx3 overexpression promotes squamous carcinoma cell survival displaying an epithelial-mesenchymal transition phenotype. (PMID:22154512)
• TBX3 CPG island methylation predicts progression in bladder cancer. (PMID:22284968)
• TBX3 promotes human embryonic stem cell proliferation and neuroepithelial differentiation in a differentiation stage-dependent manner. (PMID:22865636)
• Data show that Tbx3 is up-regulated in tissue samples of head and neck squamous cell cancer (HNSCC) patients and that Tbx3 represses PTEN transcription. (PMID:23082988)
• the sequence variants within the TBX3 gene promoter did not contribute to VSD etiology. (PMID:23116943)
• Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. (PMID:23190890)
• TBX3 gene polymorphism is associated in the development of colorectal cancers. (PMID:23266556)
• Coimmunoprecipitations and immunofluorescence analyses confirmed the L2-TBX2 interaction and revealed that human papillomavirus 16 L2 also interacts with human TBX3, another member of the T-box family. (PMID:23388722)
• TBX3 exon 2 mutation is rare in most human tumors (PMID:23656610)
• TBX3 plays a pivotal role in mediating the antiproliferative and promigratory role of TGF-beta1 in breast epithelial cells and skin keratinocytes. (PMID:24025717)
• TBX3 may play an important role as a reciprocal switch between substrate dependent cell proliferation and tumour invasion. (PMID:24098938)
• Polymorphisms in several genes involved in the Wnt signaling pathway were associated with hepatic fibrosis or inflammation risk in HCV-infected males. (PMID:24386373)
• The pleiotropic effects of TBX3 mutations in humans and mice likely result from disrupting at least two molecular functions of this protein: transcriptional regulation and pre-mRNA splicing. (PMID:24675841)
• An enhancement in TBX3 protein expression both in glomerular and tubular regions. (PMID:25158279)
• Paracrine WNT signaling is stimulated by estrogen and progesterone, while autocrine WNT signaling is induced by the embryonic T-box transcription factor TBX3 (PMID:25350852)
• Data show that the down-regulation of T-box transcription factor TBX2 by transforming growth factor beta I (TGF-beta1) is mediated by T-box transcription factor TBX3. (PMID:25371204)
• this new molecular-grade based on the combination of TBX2 and TBX3 methylation is an excellent marker for predicting progression to muscle-invasive bladder cancer in patients with primary pTaG1/2 bladder cancer. (PMID:25394776)
• TBX3 gene variants may contribute to indirect inguinal hernia as a rare risk factor by reducing TBX3 levels (PMID:25455105)

Cross-species orthologs

14 orthologs

Organism	Symbol	Gene ID
danio_rerio	tbx3a	ENSDARG00000002216
mus_musculus	Tbx3	ENSMUSG00000018604
rattus_norvegicus	Tbx3	ENSRNOG00000008706
drosophila_melanogaster	H15	FBGN0016660
drosophila_melanogaster	mid	FBGN0261963
drosophila_melanogaster	ocm	FBGN0266083
caenorhabditis_elegans		WBGENE00003106
caenorhabditis_elegans		WBGENE00004750
caenorhabditis_elegans		WBGENE00006545
caenorhabditis_elegans		WBGENE00006546
caenorhabditis_elegans		WBGENE00006556
caenorhabditis_elegans		WBGENE00006557
caenorhabditis_elegans		WBGENE00006559
caenorhabditis_elegans		WBGENE00044798

Paralogs (16): TBX21 (ENSG00000073861), TBX5 (ENSG00000089225), TBX15 (ENSG00000092607), TBX18 (ENSG00000112837), TBX2 (ENSG00000121068), TBX4 (ENSG00000121075), TBX22 (ENSG00000122145), TBR1 (ENSG00000136535), TBX19 (ENSG00000143178), TBX6 (ENSG00000149922), EOMES (ENSG00000163508), TBXT (ENSG00000164458), TBX20 (ENSG00000164532), TBX10 (ENSG00000167800), MGA (ENSG00000174197), TBX1 (ENSG00000184058)

Protein

Protein identifiers

T-box transcription factor TBX3 — O15119 (reviewed: O15119)

All UniProt accessions (1): O15119

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional repressor involved in developmental processes. Binds to the palindromic T site 5’-TTCACACCTAGGTGTGAA-3’ DNA sequence, or a half-site, which are present in the regulatory region of several genes. Probably plays a role in limb pattern formation. Required for mammary placode induction, and maintenance of the mammary buds during development. Involved in branching morphogenesis in both developing lungs and adult mammary glands, via negative modulation of target genes; acting redundantly with TBX2. Required, together with TBX2, to maintain cell proliferation in the embryonic lung mesenchyme; perhaps acting downstream of SHH, BMP and TGFbeta signaling. Involved in modulating early inner ear development, acting independently of, and also redundantly with, TBX2 in different subregions of the developing ear. Acts as a negative regulator of PML function in cellular senescence.

Subunit / interactions. Interacts with PML (isoform PML-4).

Subcellular location. Nucleus.

Tissue specificity. Widely expressed.

Disease relevance. Ulnar-mammary syndrome (UMS) [MIM:181450] Characterized by ulnar ray defects, obesity, hypogenitalism, delayed puberty, hypoplasia of nipples and apocrine glands. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. Contains an interrupted T-box domain. Contains an interrupted T-box domain. May be produced by joining exon 1 to exon 7 thereby eliminating the T-box.

Isoforms (4)

UniProt ID	Names	Canonical?
O15119-1	II	yes
O15119-2	I
O15119-3	III
O15119-4	IV

RefSeq proteins (2): NP_005987, NP_057653 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001699	TF_T-box	Family
IPR008967	p53-like_TF_DNA-bd_sf	Homologous_superfamily
IPR018186	TF_T-box_CS	Conserved_site
IPR022582	TBX2/3_TAD	Domain
IPR036960	T-box_sf	Homologous_superfamily
IPR046360	T-box_DNA-bd	Domain
IPR048387	TBX2_3_RD	Domain

Pfam: PF00907, PF12598, PF20627

UniProt features (43 total): strand 9, modified residue 8, helix 6, compositionally biased region 4, sequence conflict 4, region of interest 4, splice variant 3, DNA-binding region 2, sequence variant 2, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1H6F	X-RAY DIFFRACTION	1.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15119-F1	56.55	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 371, 432, 438, 456, 707, 738, 740, 742

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-9856649	Transcriptional and post-translational regulation of MITF-M expression and activity
R-HSA-1266738	Developmental Biology
R-HSA-9730414	MITF-M-regulated melanocyte development

MSigDB gene sets: 576 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, GOBP_CARDIAC_CHAMBER_DEVELOPMENT, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, E2F_Q4_01, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_MAMMARY_GLAND_MORPHOGENESIS, GOBP_MUSCLE_TISSUE_DEVELOPMENT, BENPORATH_ES_WITH_H3K27ME3, GOBP_CARDIAC_SEPTUM_DEVELOPMENT, GOBP_AXIS_SPECIFICATION, GOBP_GLAND_MORPHOGENESIS, GOBP_VENTRICULAR_SEPTUM_MORPHOGENESIS, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_CARDIAC_CHAMBER_MORPHOGENESIS

GO Biological Process (62): negative regulation of transcription by RNA polymerase II (GO:0000122), skeletal system development (GO:0001501), blood vessel development (GO:0001568), in utero embryonic development (GO:0001701), cell fate specification (GO:0001708), heart looping (GO:0001947), outflow tract morphogenesis (GO:0003151), atrioventricular bundle cell differentiation (GO:0003167), endocardial cushion formation (GO:0003272), DNA-templated transcription (GO:0006351), regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of cell population proliferation (GO:0008284), anterior/posterior axis specification, embryo (GO:0008595), animal organ morphogenesis (GO:0009887), specification of animal organ position (GO:0010159), stem cell population maintenance (GO:0019827), limbic system development (GO:0021761), male genitalia development (GO:0030539), female genitalia development (GO:0030540), negative regulation of epithelial cell differentiation (GO:0030857), mammary gland development (GO:0030879), regulation of protein stability (GO:0031647), luteinizing hormone secretion (GO:0032275), embryonic forelimb morphogenesis (GO:0035115), embryonic hindlimb morphogenesis (GO:0035116), forelimb morphogenesis (GO:0035136), atrioventricular canal development (GO:0036302), embryonic digit morphogenesis (GO:0042733), negative regulation of apoptotic process (GO:0043066), negative regulation of myoblast differentiation (GO:0045662), positive regulation of cell cycle (GO:0045787), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944), follicle-stimulating hormone secretion (GO:0046884), mesoderm morphogenesis (GO:0048332), semicircular canal morphogenesis (GO:0048752), smooth muscle cell differentiation (GO:0051145), roof of mouth development (GO:0060021), cardiac epithelial to mesenchymal transition (GO:0060317), ventricular septum morphogenesis (GO:0060412)

GO Molecular Function (10): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), sequence-specific DNA binding (GO:0043565), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cilium (GO:0005929)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
MITF-M-regulated melanocyte development	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	4
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
system development	2
anatomical structure morphogenesis	2
regulation of DNA-templated transcription	2
genitalia development	2
DNA-binding transcription factor activity, RNA polymerase II-specific	2
cellular anatomical structure	2
negative regulation of DNA-templated transcription	1
vasculature development	1
anatomical structure development	1
chordate embryonic development	1
cell fate commitment	1
cellular developmental process	1
embryonic heart tube morphogenesis	1
determination of heart left/right asymmetry	1
heart morphogenesis	1
bundle of His development	1
His-Purkinje system cell differentiation	1
endocardial cushion morphogenesis	1
anatomical structure formation involved in morphogenesis	1
gene expression	1
RNA biosynthetic process	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
embryonic axis specification	1
tripartite regional subdivision	1
anterior/posterior axis specification	1
animal organ development	1
regionalization	1
animal organ morphogenesis	1
multicellular organismal process	1
maintenance of cell number	1
forebrain development	1
male sex differentiation	1
reproductive system development	1
female sex differentiation	1
epithelial cell differentiation	1

Protein interactions and networks

STRING

2246 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TBX3	POU5F1	P31359	890
TBX3	NANOG	Q9H9S0	874
TBX3	KLF4	P78338	874
TBX3	SOX2	P48431	871
TBX3	RBM19	Q9Y4C8	870
TBX3	NKX2-5	P52952	867
TBX3	ESRRB	O95718	822
TBX3	SALL4	Q9UJQ4	819
TBX3	TBX5	Q99593	802
TBX3	GATA4	P43694	753
TBX3	RBM39	Q14498	745
TBX3	GJA5	P36382	722
TBX3	SHOX2	O60902	716
TBX3	HCN4	Q9Y3Q4	715
TBX3	LIF	P15018	710

IntAct

40 interactions, top by confidence:

A	B	Type	Score
TLE5	TBX3	psi-mi:“MI:0915”(physical association)	0.560
CA8	TBX3	psi-mi:“MI:0915”(physical association)	0.560
TBX3	TLE5	psi-mi:“MI:0915”(physical association)	0.560
TBX3	CA8	psi-mi:“MI:0915”(physical association)	0.560
TBX3	PRR20D	psi-mi:“MI:0915”(physical association)	0.560
TBX3	PFDN5	psi-mi:“MI:0915”(physical association)	0.560
	TBX3	psi-mi:“MI:0915”(physical association)	0.560
TBX3	CSF3	psi-mi:“MI:0915”(physical association)	0.560
TBX3	UFSP1	psi-mi:“MI:0915”(physical association)	0.560
Dlg4	TBX3	psi-mi:“MI:0407”(direct interaction)	0.440
TBX3	ANXA5	psi-mi:“MI:0915”(physical association)	0.400
PB2		psi-mi:“MI:0914”(association)	0.350
SOX2	CBX4	psi-mi:“MI:0914”(association)	0.350
HNRNPLL	TBX3	psi-mi:“MI:0914”(association)	0.350
AFG3L2	TBX3	psi-mi:“MI:0914”(association)	0.350
AKT1	TBX3	psi-mi:“MI:2364”(proximity)	0.270
BRAF	TBX3	psi-mi:“MI:2364”(proximity)	0.270
SMAD4	TBX3	psi-mi:“MI:2364”(proximity)	0.270
SPOP	TBX3	psi-mi:“MI:2364”(proximity)	0.270
TBX3	SPOP	psi-mi:“MI:2364”(proximity)	0.270
TBX3	PTPN11	psi-mi:“MI:2364”(proximity)	0.270
TBX3	PRR20D	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (93): TBX3 (Two-hybrid), TBX3 (Two-hybrid), TBX3 (Affinity Capture-Western), PLEKHF2 (Two-hybrid), TBX3 (Affinity Capture-MS), TBX3 (Affinity Capture-MS), TBX3 (Affinity Capture-MS), TBX3 (Affinity Capture-MS), TBX3 (Affinity Capture-MS), TBX3 (Affinity Capture-MS), TBX3 (Affinity Capture-MS), TBX3 (Affinity Capture-MS), TBX3 (Affinity Capture-MS), TBX3 (Affinity Capture-MS), TBX3 (Affinity Capture-MS)

ESM2 similar proteins: A4QNP7, A8TSS9, O09100, O15119, O70306, O95935, P55198, P70062, P70063, P70064, P70324, P70325, P81068, Q0VGT2, Q13207, Q25113, Q2I327, Q2MJB4, Q32NI9, Q3SA48, Q3SA49, Q4AE28, Q5UU75, Q60707, Q6GL68, Q6PCL0, Q6YHU8, Q76L87, Q7TST9, Q7ZTU9, Q800Q5, Q861Q9, Q863A2, Q86V15, Q8AX98, Q8AXX2, Q8IVH2, Q8UW76, Q90964, Q90ZB6

Diamond homologs: A1YF56, A2AWL7, D3ZJK7, E1BEA8, O01409, O13161, O15119, O15178, O17212, O43435, O54839, O60806, O70306, O73718, O75333, O95935, O95936, O95947, P20293, P24781, P55965, P56158, P57082, P70323, P70324, P70325, P70326, P70327, P79742, P79777, P79778, P79779, P79944, P80492, P87377, P90971, Q07998, Q13207, Q16650, Q17134

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
AKT3	“up-regulates activity”	TBX3	phosphorylation
TBX3	“down-regulates quantity by repression”	CDH1	“transcriptional regulation”
AKT	“up-regulates activity”	TBX3	phosphorylation
TBX3	“down-regulates quantity by repression”	CDKN1A	“transcriptional regulation”
TBX3	“down-regulates quantity by repression”	CDKN2A	“transcriptional regulation”

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 3 cancer types — BRCA, COADREAD, DLBCLNOS.

Clinical variants and AI predictions

ClinVar

670 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	22
Likely pathogenic	14
Uncertain significance	348
Likely benign	209
Benign	42

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1070549	NM_005996.4(TBX3):c.1070_1080del (p.Ala357fs)	Pathogenic
1527734	GRCh37/hg19 12q24.21(chr12:114995645-115376925)	Pathogenic
1706466	NM_005996.4(TBX3):c.1587dup (p.Ser530fs)	Pathogenic
2131719	NM_005996.4(TBX3):c.704dup (p.Arg236fs)	Pathogenic
2445206	NM_005996.4(TBX3):c.1287_1294dup (p.Glu432fs)	Pathogenic
2502305	NM_005996.4(TBX3):c.868C>T (p.Arg290Ter)	Pathogenic
2635163	NM_005996.4(TBX3):c.1141G>T (p.Glu381Ter)	Pathogenic
2709083	NM_005996.4(TBX3):c.438dup (p.Ala147fs)	Pathogenic
31909	NM_005996.4(TBX3):c.991C>T (p.Gln331Ter)	Pathogenic
3356423	NM_005996.4(TBX3):c.657+1G>A	Pathogenic
3653115	NM_005996.4(TBX3):c.510G>A (p.Trp170Ter)	Pathogenic
3669887	NM_005996.4(TBX3):c.1038dup (p.Asp347fs)	Pathogenic
4071573	NM_005996.4(TBX3):c.389+1G>A	Pathogenic
417720	NM_005996.4(TBX3):c.1423C>T (p.Gln475Ter)	Pathogenic
4279429	GRCh37/hg19 12q24.21(chr12:114686840-115741264)x1	Pathogenic
4538442	NM_005996.4(TBX3):c.1008dup (p.Ala337fs)	Pathogenic
4720369	NM_005996.4(TBX3):c.48dup (p.Tyr17fs)	Pathogenic
591004	NM_005996.4(TBX3):c.1920_1921dup (p.Pro641fs)	Pathogenic
7987	NM_005996.4(TBX3):c.227del (p.Ile76fs)	Pathogenic
7988	NM_005996.4(TBX3):c.657+1G>C	Pathogenic
7989	NM_005996.4(TBX3):c.817A>T (p.Lys273Ter)	Pathogenic
7990	NM_005996.4(TBX3):c.88dup (p.Met30fs)	Pathogenic
1709213	NM_005996.4(TBX3):c.961dup (p.Ser321fs)	Likely pathogenic
2444419	NM_005996.4(TBX3):c.1170dup (p.Ala391fs)	Likely pathogenic
3061897	NM_005996.4(TBX3):c.400C>G (p.Pro134Ala)	Likely pathogenic
3064137	NM_005996.4(TBX3):c.1921_1922insG (p.Pro641fs)	Likely pathogenic
3065230	NM_005996.4(TBX3):c.945del (p.Ser316fs)	Likely pathogenic
3075717	NM_005996.4(TBX3):c.309dup (p.Lys104fs)	Likely pathogenic
3353475	NM_005996.4(TBX3):c.390-1G>A	Likely pathogenic
3382904	NM_005996.4(TBX3):c.389+1G>T	Likely pathogenic

SpliceAI

1127 predictions. Top by Δscore:

Variant	Effect	Δscore
12:114672298:AGGCC:A	acceptor_gain	1.0000
12:114672299:GGCC:G	acceptor_gain	1.0000
12:114672300:GCC:G	acceptor_gain	1.0000
12:114672301:CC:C	acceptor_gain	1.0000
12:114672301:CCC:C	acceptor_gain	1.0000
12:114672302:CC:C	acceptor_gain	1.0000
12:114672302:CCTG:C	acceptor_loss	1.0000
12:114672303:C:CC	acceptor_gain	1.0000
12:114672303:CT:C	acceptor_loss	1.0000
12:114672308:G:C	acceptor_gain	1.0000
12:114672308:G:GC	acceptor_gain	1.0000
12:114676471:C:CC	acceptor_gain	1.0000
12:114677575:CTCA:C	donor_loss	1.0000
12:114677576:TCA:T	donor_loss	1.0000
12:114677577:CA:C	donor_loss	1.0000
12:114677578:ACC:A	donor_loss	1.0000
12:114677654:TAT:T	acceptor_gain	1.0000
12:114677654:TATC:T	acceptor_loss	1.0000
12:114677656:TC:T	acceptor_loss	1.0000
12:114677657:C:CC	acceptor_gain	1.0000
12:114677657:C:CG	acceptor_loss	1.0000
12:114679500:TTTA:T	donor_loss	1.0000
12:114679502:TA:T	donor_loss	1.0000
12:114679504:CCT:C	donor_loss	1.0000
12:114679509:T:C	donor_gain	1.0000
12:114679647:ATAGT:A	acceptor_gain	1.0000
12:114679648:TAGT:T	acceptor_gain	1.0000
12:114679650:GT:G	acceptor_gain	1.0000
12:114679650:GTCT:G	acceptor_loss	1.0000
12:114679651:TCTG:T	acceptor_loss	1.0000

AlphaMissense

4730 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:114677588:T:A	R311S	1.000
12:114677588:T:G	R311S	1.000
12:114677589:C:A	R311I	1.000
12:114677589:C:G	R311T	1.000
12:114677595:C:T	G309D	1.000
12:114677596:C:A	G309C	1.000
12:114677596:C:G	G309R	1.000
12:114677601:C:A	G307V	1.000
12:114677601:C:T	G307E	1.000
12:114677602:C:G	G307R	1.000
12:114677602:C:T	G307R	1.000
12:114677607:T:A	D305V	1.000
12:114677607:T:C	D305G	1.000
12:114677607:T:G	D305A	1.000
12:114677608:C:G	D305H	1.000
12:114677610:C:A	R304L	1.000
12:114677610:C:G	R304P	1.000
12:114677610:C:T	R304Q	1.000
12:114677611:G:A	R304W	1.000
12:114677611:G:C	R304G	1.000
12:114677612:G:C	F303L	1.000
12:114677612:G:T	F303L	1.000
12:114677613:A:C	F303C	1.000
12:114677613:A:G	F303S	1.000
12:114677614:A:C	F303V	1.000
12:114677614:A:G	F303L	1.000
12:114677614:A:T	F303I	1.000
12:114677616:C:A	G302V	1.000
12:114677616:C:T	G302D	1.000
12:114677617:C:A	G302C	1.000

dbSNP variants (sampled 300 via entrez): RS1000081459 (12:114680153 C>A,T), RS1000092646 (12:114672912 A>G), RS1000352746 (12:114684767 C>T), RS1000372007 (12:114683901 C>A,G,T), RS1000526693 (12:114673154 G>C), RS1000679028 (12:114679007 A>G), RS1000707471 (12:114684933 C>T), RS1000748022 (12:114678009 G>GCATA), RS1000785999 (12:114684967 G>A), RS1000820545 (12:114680154 G>A,C), RS1001196417 (12:114673652 C>T), RS1001217414 (12:114679281 A>G), RS1001248638 (12:114673404 G>T), RS1001251914 (12:114671217 A>C), RS1001348992 (12:114676253 T>A)

Disease associations

OMIM: gene MIM:601621 | disease phenotypes: MIM:181450, MIM:614823

GenCC curated gene-disease

Disease	Classification	Inheritance
ulnar-mammary syndrome	Definitive	Autosomal dominant
heart conduction disease	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
ulnar-mammary syndrome	Definitive	AD

Mondo (6): ulnar-mammary syndrome (MONDO:0008411), breast ductal adenocarcinoma (MONDO:0005590), eccrine porocarcinoma (MONDO:0006189), aortic valve disease 2 (MONDO:0013902), obesity disorder (MONDO:0011122), heart conduction disease (MONDO:0000992)

Orphanet (3): Ulnar-mammary syndrome (Orphanet:3138), Obesity due to melanocortin 4 receptor deficiency (Orphanet:71529), NON RARE IN EUROPE: Non rare obesity (Orphanet:521399)

HPO phenotypes

73 total (30 of 73 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000023	Inguinal hernia
HP:0000028	Cryptorchidism
HP:0000046	Small scrotum
HP:0000049	Shawl scrotum
HP:0000054	Micropenis
HP:0000089	Renal hypoplasia
HP:0000130	Abnormality of the uterus
HP:0000144	Decreased fertility
HP:0000668	Hypodontia
HP:0000768	Pectus carinatum
HP:0000813	Bicornuate uterus
HP:0000823	Delayed puberty
HP:0000882	Hypoplastic scapulae
HP:0000889	Abnormal clavicle morphology
HP:0000894	Short clavicles
HP:0000912	Sprengel anomaly
HP:0001162	Postaxial hand polydactyly
HP:0001167	Abnormal finger morphology
HP:0001231	Abnormal fingernail morphology
HP:0001513	Obesity
HP:0001601	Laryngomalacia
HP:0001607	Subglottic stenosis
HP:0001629	Ventricular septal defect
HP:0001800	Hypoplastic toenails
HP:0002021	Pyloric stenosis
HP:0002023	Anal atresia
HP:0002025	Anal stenosis
HP:0002215	Sparse axillary hair
HP:0002221	Absent axillary hair

GWAS associations

137 associations (top):

Study	Trait	p-value
GCST000396_6	Diastolic blood pressure	4.000000e-08
GCST000562_5	PR interval	3.000000e-17
GCST000919_6	Serum prostate-specific antigen levels	2.000000e-11
GCST001072_8	Blood pressure	8.000000e-07
GCST001074_2	Blood pressure	1.000000e-10
GCST001236_19	Blood pressure	4.000000e-06
GCST001489_1	Percent mammographic density	1.000000e-08
GCST001787_10	Colorectal cancer	4.000000e-07
GCST002456_6	PR segment duration	8.000000e-13
GCST002535_5	PR interval	7.000000e-07
GCST002630_14	Systolic blood pressure	2.000000e-07
GCST002829_18	Urate levels in overweight individuals	2.000000e-06
GCST003273_7	Diastolic blood pressure	8.000000e-10
GCST003542_103	Night sleep phenotypes	2.000000e-06
GCST003598_2	QRS duration	1.000000e-09
GCST003598_31	QRS duration	3.000000e-10
GCST003630_1	Left ventricular QRS voltage	8.000000e-08
GCST003872_15	QRS complex (12-leadsum)	1.000000e-17
GCST004093_38	Prostate-specific antigen levels	1.000000e-14
GCST004136_17	Methadone dose in opioid dependence	2.000000e-06
GCST004184_4	Lung function (FVC)	1.000000e-09
GCST004280_3	Diastolic blood pressure	5.000000e-13
GCST004280_72	Diastolic blood pressure	5.000000e-13
GCST004988_47	Breast cancer	4.000000e-39
GCST005588_5	Idiopathic dilated cardiomyopathy	7.000000e-06
GCST005783_4	Bone mineral density (lumbar spine) in inflammatory bowel disease	1.000000e-06
GCST005905_1	Global electrical heterogeneity phenotypes	2.000000e-24
GCST005905_2	Global electrical heterogeneity phenotypes	2.000000e-16
GCST005905_3	Global electrical heterogeneity phenotypes	1.000000e-14
GCST005978_16	Diastolic blood pressure	4.000000e-13

EFO canonical traits (24, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0004462	PR interval
EFO:0006335	systolic blood pressure
EFO:0006340	mean arterial pressure
EFO:0005095	PR segment
EFO:0004531	urate measurement
EFO:0007741	R wave amplitude
EFO:0007742	QRS amplitude
EFO:0005054	QRS complex
EFO:0007907	methadone dose measurement
EFO:0004312	vital capacity
EFO:0009094	idiopathic dilated cardiomyopathy
EFO:0007701	spine bone mineral density
EFO:0004327	electrocardiography
EFO:0004329	alcohol drinking
EFO:0006527	smoking status measurement
EFO:0009270	heel bone mineral density
EFO:0004314	forced expiratory volume
EFO:0008008	lower urinary tract symptom
EFO:0010464	beta-aminoisobutyric acid measurement
EFO:0010437	triacylglycerol 58:10 measurement
EFO:0007614	asthma exacerbation measurement
EFO:0004980	appendicular lean mass
EFO:0004532	serum gamma-glutamyl transferase measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D057090	Eccrine Porocarcinoma	C04.557.470.200.025.500
C536937	Ulnar-mammary syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

98 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tetrachlorodibenzodioxin	affects expression, increases expression	7
bisphenol A	decreases methylation, increases expression, decreases expression, affects cotreatment	5
Valproic Acid	increases expression, affects cotreatment	4
(+)-JQ1 compound	decreases expression, affects expression, increases reaction, increases expression, affects cotreatment	3
Benzo(a)pyrene	increases methylation, decreases methylation, increases expression	3
Estradiol	affects expression, affects cotreatment, increases expression	3
bisphenol S	decreases methylation, affects cotreatment, decreases expression	2
Acetaminophen	decreases expression, increases expression	2
Tobacco Smoke Pollution	increases expression	2
Tretinoin	increases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
dicrotophos	increases expression	1
methylmercuric chloride	decreases expression	1
propionaldehyde	increases expression	1
N(4)-hydroxycytidine	decreases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
terbufos	increases methylation	1
arsenite	increases methylation	1
afimoxifene	decreases reaction, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
fenvalerate	increases expression	1
butyraldehyde	increases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
coumarin	decreases phosphorylation	1
enzacamene	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
epigallocatechin gallate	increases expression, affects cotreatment	1
pentanal	increases expression	1

Cellosaurus cell lines

9 cell lines: 6 cancer cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1774	TT	Cancer cell line	Female
CVCL_5098	SNU-81	Cancer cell line	Male
CVCL_A7A8	SEES3-1V human TBX3, clone1	Embryonic stem cell	Male
CVCL_A7A9	SEES3-1V human TBX3, clone2	Embryonic stem cell	Male
CVCL_A8L5	SEES3-1V human TBX3, clone3	Embryonic stem cell	Male
CVCL_D1ZA	Abcam A-549 TBX3 KO	Cancer cell line	Male
CVCL_D2DB	Abcam HCT 116 TBX3 KO	Cancer cell line	Male
CVCL_TR77	HAP1 TBX3 (-) 1	Cancer cell line	Male
CVCL_TR78	HAP1 TBX3 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00076362	PHASE4	COMPLETED	Pediatric Hypothalamic Obesity
NCT00079547	PHASE4	COMPLETED	The Safety and Effectiveness of Low and High Carbohydrate Diets
NCT00115063	PHASE4	TERMINATED	LOSS- Louisiana Obese Subjects Study
NCT00134303	PHASE4	COMPLETED	Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
NCT00143936	PHASE4	COMPLETED	The Safety and Efficacy of Low and High Carbohydrate Diets
NCT00143962	PHASE4	COMPLETED	Comparison of Two Approaches to Weight Loss Follow-Up Study
NCT00152360	PHASE4	COMPLETED	The Effect of Xenical on Weight and Risk Factors
NCT00176306	PHASE4	COMPLETED	Levofloxacin Pharmacokinetics (PK) in the Severely Obese
NCT00203450	PHASE4	COMPLETED	Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial
NCT00205504	PHASE4	COMPLETED	Oral Contraceptives in the Metabolic Syndrome
NCT00229229	PHASE4	TERMINATED	Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease
NCT00234988	PHASE4	COMPLETED	A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
NCT00264589	PHASE4	COMPLETED	Exercise Training and Cardiovascular Function in Obesity and in Type 2 Diabetes
NCT00288873	PHASE4	COMPLETED	Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
NCT00298857	PHASE4	TERMINATED	A Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights
NCT00315146	PHASE4	COMPLETED	Optimizing Body Composition for Function in Older Adults
NCT00319202	PHASE4	TERMINATED	Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects
NCT00327912	PHASE4	UNKNOWN	Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal Switch for Superobesity
NCT00352287	PHASE4	COMPLETED	Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
NCT00353054	PHASE4	COMPLETED	Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.
NCT00390637	PHASE4	COMPLETED	Diet, Obesity and Genes (DiOGenes)
NCT00415688	PHASE4	COMPLETED	Lifestyle Modification for Obesity-Related Type 2 Diabetes
NCT00433641	PHASE4	COMPLETED	Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
NCT00440375	PHASE4	COMPLETED	Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women
NCT00453557	PHASE4	COMPLETED	Mechanism of Growth Hormone Effects on Adipose Tissue
NCT00456885	PHASE4	COMPLETED	The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
NCT00463112	PHASE4	COMPLETED	Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS
NCT00512187	PHASE4	COMPLETED	Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
NCT00516919	PHASE4	COMPLETED	Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
NCT00522470	PHASE4	COMPLETED	Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels
NCT00537810	PHASE4	COMPLETED	Treatment of Binge Eating in Obese Patients in Primary Care
NCT00538486	PHASE4	COMPLETED	A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients
NCT00584389	PHASE4	TERMINATED	The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition
NCT00585182	PHASE4	COMPLETED	Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
NCT00632840	PHASE4	COMPLETED	Pharmacological Regulation of Fat Transport in Metabolic Syndrome
NCT00636142	PHASE4	COMPLETED	Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity
NCT00675987	PHASE4	COMPLETED	A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients
NCT00694811	PHASE4	COMPLETED	Effects of Re-Feeding Duration on Weight Maintenance After Weight Loss With Very-Low-Energy Diets (VLEDs)
NCT00699413	PHASE4	TERMINATED	Supplements for Controlling Resistance to Insulin
NCT00729963	PHASE4	COMPLETED	Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients